Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant

Journal of Virology

Volumn 82, Issue 1, 2008, Pages 246-253

  Chou, Sunwen ^a,b   Marousek, Gail I ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZIMIDAVIR; CIDOFOVIR; EXONUCLEASE; FOSCARNET; GANCICLOVIR; POL PROTEIN; PROTEIN UL54; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CODON; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS STRAIN D413A; CYTOMEGALOVIRUS STRAIN T2294; CYTOMEGALOVIRUS STRAIN UL97; GENE TRANSFER; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; STRAIN DIFFERENCE; STRAIN IDENTIFICATION; VIRUS MUTATION; VIRUS PLAQUE; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PHOSPHONIC ACIDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN STRUCTURE, TERTIARY; RIBONUCLEOSIDES; SEQUENCE ALIGNMENT; VIRAL PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MUSHROOM BACILLIFORM VIRUS;

EID: 37349039721     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01787-07     Document Type: Article

References (31)

1. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
2. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
3. Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
4. Chou, S., and G. I. Marousek. 2006. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 50:3470-3472.
5. Chou, S., G. I. Marousek, A. E. Senters, M. G. Davis, and K. K. Biron. 2004. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78:7124-7130.
6. Chou, S., L. C. Van Wechel, H. M. Lichy, and G. I. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49:2710-2715.
7. Chou, S., L. C. van Wechel, and G. I. Marousek. 2007. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196:91-94.
8. Chou, S., L. C. Van Wechel, and G. I. Marousek. 2006. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob. Agents Chemother. 50:2557-2559.
9. Drew, W. L., R. C. Miner, G. I. Marousek, and S. Chou. 2006. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37:124-127.
10. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
11. Hall, J. D., K. L. Orth, K. L. Sander, B. M. Swihart, and R. A. Senese. 1995. Mutations within conserved motifs in the 3′-5′ exonuclease domain of herpes simplex virus DNA polymerase. J. Gen. Virol. 76:2999-3008.
12. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
13. He, Z., Y. S. He, Y. Kim, L. Chu, C. Ohmstede, K. K. Biron, and D. M. Coen. 1997. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 71:405-411.
14. Hwang, Y. T., B. Y. Liu, D. M. Coen, and C. B. Hwang. 1997. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J. Virol. 71:7791-7798.
15. Komazin, G., R. G. Ptak, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2003. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Virol. 77:11499- 11506.
16. Krosky, P. M., M. C. Back, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
17. Krosky, P. M., M. C. Baek, W. J. Jahng, I. Barrera, R. J. Harvey, K. K. Biron, D. M. Coen, and P. B. Sethna. 2003. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77:7720-7727.
18. Kuhn, F. J., and C. W. Knopf. 1996. Herpes simplex virus type 1 DNA polymerase. Mutational analysis of the 3′-5′-exonuclease domain. J. Biol. Chem. 271:29245-29254.
19. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
20. Liu, S., J. D. Knafels, J. S. Chang, G. A. Waszak, E. T. Baldwin, M. R. Deibel, Jr., D. R. Thomsen, F. L. Homa, P. A. Wells, M. C. Tory, R. A. Poorman, H. Gao, X. Qiu, and A. P. Seddon. 2006. Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 281:18193-18200.
21. Lund, O., M. Nielsen, C. Lundegaard, and P. Worning. 2002. CPHmodels 2.0: X3M, a computer program to extract 3D models, abstr. A102. CASP5 conference.
22. Marfori, J. E., M. M. Exner, G. I. Marousek, S. Chou, and W. L. Drew. 2007. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J. Clin. Virol. 38:120-125.
23. Marschall, M., M. Freitag, P. Suchy, D. Romaker, R. Kupfer, M. Hanke, and T. Stamminger. 2003. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311:60-71.
24. Ngo, J. C., S. Chakrabarti, J. H. Ding, A. Velazquez-Dones, B. Nolen, B. E. Aubol, J. A. Adams, X. D. Fu, and G. Ghosh. 2005. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol. Cell 20:77-89.
25. Padyana, A. K., H. Qiu, A. Roll-Mecak, A. G. Hinnebusch, and S. K. Burley. 2005. Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J. Biol. Chem. 280:29289-29299.
26. Prichard, M. N., W. J. Britt, S. L. Daily, C. B. Hartline, and E. R. Kern. 2005. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79:15494-15502.
27. Prichard, M. N., N. Gao, S. Jairath, G. Mulamba, P. Krosky, D. M. Coen, B. O. Parker, and G. S. Pari. 1999. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670.
28. Sarisky, R. T., T. T. Nguyen, K. E. Duffy, R. J. Wittrock, and J. J. Leary. 2000. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 44:1524-1529.
29. Truesdale, A. T., K. K. Biron, B. P. Ellis, W. H. Miller, and E. R. Wood. 2007. Mode of inhibition studies with MBV and the CMV kinase UL97, abstr. 10.27. 32nd Int. Herpesvirus Workshop, Asheville, NC.
30. Warming, S., N. Costantino, D. L. Court, N. A. Jenkins, and N. G. Copeland. 2005. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33:e36.
31. Wolf, D. G., C. T. Courcelle, M. N. Prichard, and E. S. Mocarski. 2001. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. USA 98:1895-1900.